Aseptic fill and finish scope: choosing the container closure system before the line, what a fill finish cdmo has to demonstrate in its media fills and environmental monitoring, and where syringe filling machines change the validation entirely
Fill and finish is the last operation and the one that most often delays a programme, because contamination control is a facility property rather than a process parameter. The decisions that matter are made long before the first batch: the container, the closure, the line, and the evidence the site can already produce. This page covers how to scope it and what to ask a provider.
- the environment the open container and the filling needle sit in
- Grade A
- the media fill acceptance criterion, contaminated units permitted
- 0 units
- the good manufacturing practice regulation the operation runs under
- Part 211
Figures in this panel are the environmental grade, the media fill acceptance criterion and the regulation an aseptic operation runs under, named from the guidance and the regulations themselves and linked in the sources below. They are identifiers, not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a manufacturing price index it has not measured.
- 4 vendor service pages verifiedevery figure matched verbatim to the vendor's page
- Quoted and dated, never estimatedlast verification pass 2026-08-24
- 1 service classes coveredeach with measured search demand behind it
Scoping the operation
- Choose the container closure system first. Vial, prefilled syringe or cartridge decides the line, the stoppering, the inspection and much of the stability work. Changing it later is effectively restarting. Decide it from the route of administration and the intended user, not from what the site already runs.
- Establish the product's tolerances before the line is selected. Shear sensitivity, silicone oil interaction, tungsten residue from syringe manufacture and surface adsorption all attack biologics in ways that only appear in the final container. Small scale studies on these cost weeks; discovering them at engineering batch costs months.
- Ask for the site's media fill history, not its capability statement. Three consecutive successful media fills at the scale and line you would use, with the interventions represented, and an acceptance criterion of no contaminated units. Ask what interventions were simulated, because a media fill without the hard interventions proves little.
- Read the environmental monitoring data. Grade A monitoring results over a period, with excursion investigations and how they were closed, tell you more about a facility than any tour. A site unwilling to share trended data under confidentiality is telling you something.
- Fix container closure integrity testing early. Deterministic methods such as helium leak or high voltage leak detection have largely replaced the dye ingress test, and the method has to be developed for your specific container. This is routinely left until stability is already running.
Technology transfer and the engineering batch
Transfer is a documentation exercise and a scale exercise at once. Hold times, filter compatibility and extractables, mixing at the new vessel geometry and line speed all have to be re-established, and the engineering batch is where they are found.
Budget for at least one engineering batch that produces nothing saleable. Programmes that plan straight into a clinical batch tend to produce an investigation instead.
Inspection and what counts as a defect
Every unit is inspected, manually or automatically, and the defect library has to be agreed and the inspectors qualified against it. For a protein product, particles are where the argument happens, because the product itself can form them.
Agree the accept and reject criteria before the first batch, with images. A defect library written after a batch has been inspected is a negotiation rather than a specification.
Scheduling reality
Sterile lines are booked far ahead and a slot missed is usually a quarter lost. Confirm the slot, the campaign length and what happens if your material is late, because the penalty terms tell you how real the slot is.
Secondary packaging, labelling for the destination markets and release testing sit after the fill and routinely add weeks nobody planned for. Map them onto the timeline before committing to a clinical start date.
Common questions
- What does aseptic fill and finish cover?
- Formulation of the final drug product, sterile filtration, filling into the primary container, stoppering and sealing, inspection, and labelling and packaging. It is the step where the product becomes the thing a patient receives.
- How do I choose a fill finish cdmo?
- On the container formats it runs routinely, its media fill and environmental monitoring record, its inspection capability, and slot availability. Capacity in eighteen months is not capacity, and the format it runs occasionally is the one that will cause problems.
- What changes with syringe filling machines?
- Prefilled syringes bring silicone lubrication, the plunger and the needle shield into the product contact picture, plus functional testing of break-loose and glide force. It is a materially larger validation exercise than vials.
- What is the acceptance criterion for a media fill?
- No contaminated units, with any positive triggering a full investigation. Three consecutive successful runs are the conventional qualification, with periodic requalification and any significant change requiring repetition.
Get a shortlist for your project
Browse by service class
Sources
Cite or embed this figure
The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.
Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/aseptic-fill-and-finish/.